Leerink Partnrs Issues Positive Estimate for AbbVie Earnings

AbbVie Inc. (NYSE:ABBV) – Leerink Partnrs boosted their FY2025 EPS estimates for shares of AbbVie in a report issued on Monday, April 28th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $12.20 for the year, up from their previous forecast of $12.09. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie’s FY2027 earnings at $15.61 EPS.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.40 by $0.06. The firm had revenue of $13.34 billion during the quarter, compared to analysts’ expectations of $12.91 billion. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. AbbVie’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.31 EPS.

ABBV has been the topic of several other research reports. The Goldman Sachs Group restated a “neutral” rating and set a $194.00 target price on shares of AbbVie in a report on Tuesday, April 8th. Wells Fargo & Company upped their target price on AbbVie from $210.00 to $240.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. UBS Group raised their target price on AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Morgan Stanley upped their price target on AbbVie from $241.00 to $250.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Raymond James reiterated an “outperform” rating and set a $220.00 price objective (up previously from $218.00) on shares of AbbVie in a research note on Monday, February 3rd. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $211.41.

AbbVie Stock Down 0.9 %

Shares of NYSE:ABBV opened at $193.40 on Thursday. The stock has a 50-day simple moving average of $196.25 and a 200-day simple moving average of $187.20. The stock has a market capitalization of $342.11 billion, a P/E ratio of 80.58, a PEG ratio of 1.62 and a beta of 0.55. AbbVie has a 1 year low of $153.58 and a 1 year high of $218.66. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66.

Institutional Investors Weigh In On AbbVie

Large investors have recently made changes to their positions in the company. Mitchell Mcleod Pugh & Williams Inc. grew its position in AbbVie by 0.8% during the 1st quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 15,483 shares of the company’s stock worth $3,244,000 after purchasing an additional 130 shares in the last quarter. Cutter & CO Brokerage Inc. grew its holdings in shares of AbbVie by 9.5% during the first quarter. Cutter & CO Brokerage Inc. now owns 7,744 shares of the company’s stock valued at $1,622,000 after buying an additional 672 shares in the last quarter. Rice Hall James & Associates LLC raised its position in AbbVie by 9.3% during the first quarter. Rice Hall James & Associates LLC now owns 5,144 shares of the company’s stock valued at $1,078,000 after buying an additional 437 shares during the period. Bleakley Financial Group LLC lifted its stake in AbbVie by 11.6% in the 1st quarter. Bleakley Financial Group LLC now owns 66,616 shares of the company’s stock worth $13,957,000 after acquiring an additional 6,934 shares in the last quarter. Finally, Key Financial Inc lifted its stake in AbbVie by 2.6% in the 1st quarter. Key Financial Inc now owns 16,027 shares of the company’s stock worth $3,358,000 after acquiring an additional 412 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In other news, EVP Timothy J. Richmond sold 29,917 shares of the company’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the completion of the sale, the executive vice president now directly owns 44,284 shares of the company’s stock, valued at $8,985,223.60. This represents a 40.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of AbbVie stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $210.08, for a total value of $12,359,426.56. Following the completion of the transaction, the executive vice president now directly owns 53,234 shares in the company, valued at $11,183,398.72. This represents a 52.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,471 shares of company stock valued at $23,426,451. Corporate insiders own 0.25% of the company’s stock.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a dividend yield of 3.39%. The ex-dividend date is Tuesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 279.15%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.